Uniqure (NASDAQ:QURE) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday.
A number of other research firms have also recently issued reports on QURE. HC Wainwright set a $28.00 price target on shares of Uniqure and gave the company a “buy” rating in a report on Thursday, December 7th. Janney Montgomery Scott started coverage on shares of Uniqure in a report on Wednesday, January 3rd. They set a “buy” rating and a $25.00 price target for the company. Zacks Investment Research cut shares of Uniqure from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Oppenheimer reaffirmed a “hold” rating on shares of Uniqure in a research report on Friday, November 24th. Finally, ValuEngine lowered shares of Uniqure from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.38.
Shares of QURE stock opened at $23.07 on Friday. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure has a fifty-two week low of $4.72 and a fifty-two week high of $27.19. The stock has a market cap of $730.95, a PE ratio of -7.85 and a beta of 0.09.
A number of large investors have recently bought and sold shares of QURE. Macquarie Group Ltd. raised its position in Uniqure by 660.1% in the fourth quarter. Macquarie Group Ltd. now owns 532,049 shares of the biotechnology company’s stock worth $10,423,000 after purchasing an additional 462,049 shares in the last quarter. BlackRock Inc. raised its position in Uniqure by 999.6% in the fourth quarter. BlackRock Inc. now owns 468,422 shares of the biotechnology company’s stock worth $9,177,000 after purchasing an additional 425,823 shares in the last quarter. RTW Investments LP acquired a new position in Uniqure in the fourth quarter worth about $7,905,000. Prosight Management LP acquired a new position in Uniqure in the fourth quarter worth about $5,578,000. Finally, Bogle Investment Management L P DE acquired a new position in Uniqure in the fourth quarter worth about $3,553,000. 43.98% of the stock is owned by hedge funds and other institutional investors.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.